327 related articles for article (PubMed ID: 26890290)
1. Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.
Pusceddu S; Buzzoni R; Vernieri C; Concas L; Marceglia S; Giacomelli L; Milione M; Leuzzi L; Femia D; Formisano B; Mazzaferro V; de Braud F
Future Oncol; 2016 May; 12(10):1251-60. PubMed ID: 26890290
[TBL] [Abstract][Full Text] [Related]
2. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
Pusceddu S; Vernieri C; Di Maio M; Marconcini R; Spada F; Massironi S; Ibrahim T; Brizzi MP; Campana D; Faggiano A; Giuffrida D; Rinzivillo M; Cingarlini S; Aroldi F; Antonuzzo L; Berardi R; Catena L; De Divitiis C; Ermacora P; Perfetti V; Fontana A; Razzore P; Carnaghi C; Davì MV; Cauchi C; Duro M; Ricci S; Fazio N; Cavalcoli F; Bongiovanni A; La Salvia A; Brighi N; Colao A; Puliafito I; Panzuto F; Ortolani S; Zaniboni A; Di Costanzo F; Torniai M; Bajetta E; Tafuto S; Garattini SK; Femia D; Prinzi N; Concas L; Lo Russo G; Milione M; Giacomelli L; Buzzoni R; Delle Fave G; Mazzaferro V; de Braud F
Gastroenterology; 2018 Aug; 155(2):479-489.e7. PubMed ID: 29655834
[TBL] [Abstract][Full Text] [Related]
3. Metformin and everolimus in neuroendocrine tumours: A synergic effect?
Hue-Fontaine L; Lemelin A; Forestier J; Raverot G; Milot L; Robinson P; Borson-Chazot F; Lombard-Bohas C; Walter T
Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):954-960. PubMed ID: 32146090
[TBL] [Abstract][Full Text] [Related]
4. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
Pusceddu S; de Braud F; Concas L; Bregant C; Leuzzi L; Formisano B; Buzzoni R
Tumori; 2014; 100(6):e286-9. PubMed ID: 25688512
[TBL] [Abstract][Full Text] [Related]
5. Metformin and pancreatic cancer: a clue requiring investigation.
Pollak M
Clin Cancer Res; 2012 May; 18(10):2723-5. PubMed ID: 22465829
[TBL] [Abstract][Full Text] [Related]
6. A novel insight into the anticancer mechanism of metformin in pancreatic neuroendocrine tumor cells.
Vitali E; Boemi I; Piccini S; Tarantola G; Smiroldo V; Lavezzi E; Brambilla T; Zerbi A; Carnaghi C; Mantovani G; Spada A; Lania AG
Mol Cell Endocrinol; 2020 Jun; 509():110803. PubMed ID: 32251713
[TBL] [Abstract][Full Text] [Related]
7. Early Response to Everolimus Therapy Detected on 68Ga-DOTATATE PET/CT in a Patient With Pancreatic Neuroendocrine Tumor.
Ozkan E; Soydal C; Ucak Semirgin S; Yapici O; Atmaca A; Demirag G
Clin Nucl Med; 2016 Jul; 41(7):561-3. PubMed ID: 27163457
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy and metformin in pancreatic adenocarcinoma and neuroendocrine tumors.
Burney S; Khawaja KI; Saif MW; Masud F
JOP; 2014 Jul; 15(4):313-6. PubMed ID: 25076330
[TBL] [Abstract][Full Text] [Related]
9. Role of everolimus in pancreatic neuroendocrine tumors.
Goldstein R; Meyer T
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
[TBL] [Abstract][Full Text] [Related]
10. Everolimus plus octreotide long-acting repeatable in advanced neuroendocrine tumors in the routine tertiary cancer care setting: An Indian experience.
Tippeswamy R; Patil S; Sateesh CT; Shashidhara HP; Prabhudesai S; Prashanth P; Haridas KM
Indian J Cancer; 2015; 52(3):359-62. PubMed ID: 26905137
[TBL] [Abstract][Full Text] [Related]
11. Impact of everolimus on Japanese patients with advanced pancreatic neuroendocrine neoplasms.
Lee L; Ito T; Igarashi H; Ueda K; Fujiyama T; Kawabe K; Ogawa Y
J Hepatobiliary Pancreat Sci; 2017 Feb; 24(2):95-102. PubMed ID: 27926987
[TBL] [Abstract][Full Text] [Related]
12. Novel agents in gastroenteropancreatic neuroendocrine tumors.
Stevenson R; Libutti SK; Saif MW
JOP; 2013 Mar; 14(2):152-4. PubMed ID: 23474560
[TBL] [Abstract][Full Text] [Related]
13. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.
Raj N; Reidy-Lagunes D
Hematol Oncol Clin North Am; 2016 Feb; 30(1):119-33. PubMed ID: 26614372
[TBL] [Abstract][Full Text] [Related]
14. Symptomatic Control of Neuroendocrine Tumours with Everolimus.
Bainbridge HE; Larbi E; Middleton G
Horm Cancer; 2015 Dec; 6(5-6):254-9. PubMed ID: 26245686
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic neuroendocrine neoplasms.
Hörsch D; Bert T; Schrader J; Hommann M; Kaemmerer D; Petrovitch A; Zaknun J; Baum RP
Minerva Gastroenterol Dietol; 2012 Dec; 58(4):401-26. PubMed ID: 23207615
[TBL] [Abstract][Full Text] [Related]
16. Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET).
De Gennaro Colonna V; Pavanello C; Rusconi F; Sartore-Bianchi A; Siena S; Castelnuovo S; Sirtori CR; Mombelli G
J Clin Pharm Ther; 2018 Feb; 43(1):114-116. PubMed ID: 28730672
[TBL] [Abstract][Full Text] [Related]
17. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.
Lombard-Bohas C; Yao JC; Hobday T; Van Cutsem E; Wolin EM; Panneerselvam A; Stergiopoulos S; Shah MH; Capdevila J; Pommier R
Pancreas; 2015 Mar; 44(2):181-9. PubMed ID: 25479584
[TBL] [Abstract][Full Text] [Related]
18. Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives.
Gallo M; Malandrino P; Fanciulli G; Rota F; Faggiano A; Colao A;
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1209-1224. PubMed ID: 28405826
[TBL] [Abstract][Full Text] [Related]
19. Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome it.
Capozzi M; Caterina I; De Divitiis C; von Arx C; Maiolino P; Tatangelo F; Cavalcanti E; Di Girolamo E; Iaffaioli RV; Scala S; Tafuto S;
Int J Surg; 2015 Sep; 21 Suppl 1():S89-94. PubMed ID: 26123382
[TBL] [Abstract][Full Text] [Related]
20. Advances in pancreatic neuroendocrine tumor treatment.
van der Veldt AA; Kleijn SA
N Engl J Med; 2011 May; 364(19):1873; author reply 1873-5. PubMed ID: 21561355
[No Abstract] [Full Text] [Related]
[Next] [New Search]